- Kelun Pharma reported a net income of 2.94 billion yuan for the fiscal year.
- The company’s revenue for the same period was recorded at 21.81 billion yuan.
- Investment analysts largely favor Kelun Pharma with 17 buy recommendations.
- The stock has received 2 hold recommendations and no sell recommendations, indicating a positive outlook.
A look at Sichuan Kelun Pharmaceutical Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts assessing Sichuan Kelun Pharmaceutical‘s long-term outlook using Smartkarma Smart Scores see a positive trend ahead. With a Growth score of 5, the company is positioned for strong future expansion and development within the pharmaceutical industry. Complementing this, Sichuan Kelun also received high scores in Dividend, Resilience, and Momentum, indicating solid performance in these areas. While the Value score is slightly lower at 3, the overall outlook remains promising for this pharmaceutical manufacturer.
Sichuan Kelun Pharmaceutical Co., Ltd., known for its diverse range of pharmaceutical products, stands out as a company focused on innovation and growth. Primarily manufacturing large infusion products, tablets, antibiotics, and traditional Chinese medicine, the company has established its presence in the market. The high Smartkarma Smart Scores reflect Sichuan Kelun’s commitment to delivering value to its shareholders while maintaining strong growth momentum and resilience in the face of market challenges.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
